Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Patent
1994-04-12
1997-02-18
Henley, III, Raymond
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
514256, 514336, 514349, 514351, 514365, 514370, 514374, 514377, 514392, 514422, 514426, 514432, 514469, 514471, 514472, A61K 31495, A61K 31505, A61K 3144, A61K 3141, A61K 3142, A61K 31415, A61K 3140, A61K 3138, A61K 3134
Patent
active
056042280
ABSTRACT:
N,N-disubstituted-guanidines, e.g., of the formula ##STR1## wherein R and R' are substituted or unsubstituted hydrocarbon groups. Methods are provided for the treatment of psychosis and hypertension by administering an effective amount of an N,N'-disubstituted guanidine which, preferably, has a high affinity for the sigma receptor.
REFERENCES:
patent: 1422506 (1922-07-01), Weiss
patent: 1597233 (1926-08-01), Heuser et al.
patent: 1642180 (1927-09-01), Scott
patent: 1672431 (1928-06-01), Schotte
patent: 1756315 (1930-04-01), Ter Horst
patent: 1795738 (1931-03-01), Schotte
patent: 1850682 (1932-03-01), Meiss
patent: 1915922 (1933-06-01), Christman et al.
patent: 2145214 (1939-01-01), Jayne, Jr.
patent: 2254009 (1941-08-01), Hechenbleikner
patent: 2274476 (1942-02-01), Hechenbleikner
patent: 2362915 (1944-11-01), MacGregor
patent: 2633474 (1953-03-01), Beaver
patent: 3121645 (1964-02-01), Bindler et al.
patent: 3140231 (1964-07-01), Luskin et al.
patent: 3159676 (1964-12-01), Spickett et al.
patent: 3193453 (1965-07-01), Quinn
patent: 3228975 (1966-01-01), Abraham et al.
patent: 3248426 (1966-04-01), Dvornik
patent: 3270054 (1966-08-01), Gagneux et al.
patent: 3283003 (1966-11-01), Jack et al.
patent: 3301755 (1967-01-01), Mull
patent: 3320229 (1967-05-01), Szabo et al.
patent: 3409669 (1968-11-01), Dyke
patent: 3479437 (1969-11-01), Szabo et al.
patent: 3547951 (1970-12-01), Hardie et al.
patent: 3639477 (1972-02-01), L'Italien
patent: 3681459 (1972-08-01), Hughes et al.
patent: 3723463 (1973-03-01), Yale et al.
patent: 3769427 (1973-10-01), Hughes et al.
patent: 3804898 (1974-04-01), Panneman
patent: 3908013 (1975-09-01), Hughes et al.
patent: 3968243 (1976-07-01), Maxwell et al.
patent: 3976643 (1976-08-01), Diamond et al.
patent: 3976787 (1976-08-01), Hughes et al.
patent: 4007181 (1977-02-01), DuCharme et al.
patent: 4014934 (1977-03-01), Hughes et al.
patent: 4051256 (1977-09-01), Swallow
patent: 4052455 (1977-10-01), Matier et al.
patent: 4109014 (1978-08-01), Liu et al.
patent: 4130663 (1978-12-01), Matier et al.
patent: 4169154 (1979-09-01), Cohen et al.
patent: 4284642 (1981-08-01), Toldy et al.
patent: 4369325 (1983-01-01), Toldy et al.
patent: 4400383 (1983-08-01), Davidson et al.
patent: 4470989 (1984-09-01), Henning et al.
patent: 4471137 (1984-09-01), Barton et al.
patent: 4575514 (1986-03-01), Carson
patent: 4709094 (1987-11-01), Weber et al.
patent: 4780466 (1988-10-01), Hrib et al.
patent: 4898978 (1990-02-01), Bergfeld et al.
patent: 4906779 (1990-03-01), Weber et al.
patent: 5093525 (1992-03-01), Weber et al.
patent: 5190976 (1993-03-01), Weber et al.
patent: 5262568 (1993-11-01), Weber et al.
patent: 5312840 (1994-05-01), Keana et al.
F. Monnet et al., "Multiple Sigma and PCP Receptor Ligands: Mechanism For Neuromodulation and Protection", (1991).
A. Wilson et al., J. Nuclear. Medicine, 31(5):747, abstract No. 376 (1990).
B. Cambell et al., European Journal of Pharmacology, 205:219-233 (1991).
T. Massamiri et al., The Journal of Pharmacology and Experimental Therapeutics, 259(1):22-29 (1991).
J. T. Adams et al., Eur. J. Pharm., 142:61-71 (1987).
P. N. Bhargava et al., Chemical Abstracts, 86:598, 189787b (1977).
W. D. Bowen et al., Eur. J. Pharm., 147:153-154 (1988).
B. G. Campbell et al., J. Neurosci., 9(10):3380-3391 (1989).
I. V. Dranka et al., Russian J. Inorg. Chem., 26(3):347-350 (1981).
G. J. Durant et al., J. Med. Chem., 28:1414-1422 (1985).
S. E. File, TINS, 10:461-463 (1987).
H. W. Geluk et al., J. Med. Chem., 12:712-715 (1969).
M. P. Kavanaugh et al., Proc. Natl. Acad. Sci. USA, 85:2844-2848 (1988).
C. A. Maryanoff et al., J. Org. Chem., 51:1882-1884 (1986).
S. R. Safir et al., J. Org. Chem., 13:924-932 (1948).
M. W. Scherz et al., J. Med. Chem., 33:2421-2429 (1990).
M. S. Sonders et al., TINS, 11:37-40 (1988).
A. A. Stolyarchuk et al., Chemical Abstracts, 86:522-523, 121071h (1977).
B. Tester et al., Society for Neuroscience, 19th Annual Meeting, p. 983, 396.17 (1989).
T. J. R. Weakley et al., Acta Cryst., 46:2234-2236 (1990).
W. Weber et al., Proc. Natl. Acad. Sci. USA, 83:8784-8788 (1986).
H. G. M. Westenberg et al., Psychopharmacol. Bull., 23:145-149 (1987).
International Search Report for International Application No. PCT/US90/02398, filed May 2, 1990.
J. Fischer et al., "High-Affinity Binding of [.sup.3 H] Adamantyl-Tolyl Guanidines To The Sigma Receptor", abstract No. 159.13, vol. 16, Society for NeuroScience Abstracts (1990).
Keana John F. W.
Weber Eckard
Conlin David G.
Corless Peter F.
Henley III Raymond
State of Oregon acting by and through the Oregon State Board of
University of Oregon
LandOfFree
Substituted guanidines having high binding to the sigma receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Substituted guanidines having high binding to the sigma receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Substituted guanidines having high binding to the sigma receptor will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-1602658